News By Tag
* Urinary exosomes
* Urine Proteomics
* Albumin Depletion
* Urinary Protein Profiling
* More Tags...
News By Location
Research Article Cites AlbuSorb™ to Improve Urine Exosome Proteomic Study
Authors Zubiri et al, cite AlbuSorb™ for albumin depletion and further describe proteomic workflows for biomarker discovery from isolated urine exosomes.
Zubiri, Irene, Maria Posada-Ayala, Aroa Sanz-Maroto, Enrique Calvo, Marta Martin-Lorenzo, Laura Gonzalez-Calero, Fernando de la Cuesta et al. "Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis." Journal of Proteomics, 96 (2014): 92-102.
In brief, the article states that diabetes mellitus leads to diabetic nephropathy (DN), ultimately causing end-stage renal disease (ESRD). So discovery of candidate biomarkers which identify the pathophysiological mechanism of DN remain important. Identification of such biomarker proteins from diabetic nephropathy (DN) and healthy human urine samples is challenged by the high abundance proteins present in urine, especially albumin and Tamm-Horsfall protein. Secreted microvesicles known as exosomes are linked to antigen expression, RNA and protein transport. Exosomes extracted from urine samples could become a rich source of urinary biomarkers, and may supplement serum creatinine and albumin excretion, for disease staging and clinical intervention. In this article, exosome isolation via ultracentrifugation, dithiothreitol (DTT) treatment, and albumin depletion of precipitated exosome fractions is described. Authors Zubiri et al, cite AlbuSorb™ for albumin depletion and further describe proteomic workflows for biomarker discovery from isolated urine exosomes. Subsequent LC-MS/MS and selected reaction monitoring (SRM) of urine exosome protein content from diabetic and healthy controls were analyzed. The research cites AMBP, MLL3, VDAC1 as proteins in urinary exosomes of diabetic nephropathy patients.
“This article further validates our unique surface technology, not based on antibodies or engineered bio-ligands, as being a highly selective and efficient method for the depletion of albumin from any biological source. I am delighted to see that such efficiencies lead to the enhanced contribution of proteomics to understand and treat disease.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
Characteristics of AlbuSorb™
Removes >90% albumin from 30 mg albumin/ml sample
Affinity-type equivalence, virtually no cross-reactivity with other proteins
Bind and elute procedure - simply weigh powder, condition the sample, centrifuge and/or filter, and recover the albumin depleted serum
Economical new surface technology, not based on biologically derived ligands
Mild conditions maintain tertiary structure of proteins and simple transfer to secondary analysis
The albumin depleted filtrate retains all enzymatic and biological activity
Tissue and species agnostic
The flow through fraction is compatible with LC-MS, activity based protein profiling and all proteomic analyses.
For more information visit: AlbuSorb ™ albumin depletion kit visit:
About Biotech Support Group LLC
Biotech Support Group LLC is a leading developer of proteomic, metabolomic and genomic sample preparation and enrichment products. It’s principal products include: AlbuVoid™ & AlbuSorb™ for albumin depletion, Cleanascite™
Biotech Support Group
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
800-935-0628 North America
Biotech Support Group